Our response to the daraxonrasib clinical study and KRAS inhibitors

At the 2026 American Society of Clinical Oncology’s annual meeting, the latest results from the clinical trial investigating whether the drug, daraxonrasib can be effectively used as a treatment for late-stage pancreatic cancer were presented.

Our Director of Services, Research and Innovation, Anna Jewell comments on these findings, and the promise of treatments that target KRAS mutations (pronounced K – ras).

“These new treatments targeting KRAS mutations are some of the most exciting developments we have seen in pancreatic cancer for a very long time. KRAS mutations are found in over 90% of all pancreatic tumours and are responsible for driving the rapid growth of this devastating disease.

“By blocking the activity of KRAS mutations, this drug, daraxonrasib, has been shown to improve survival in people with advanced pancreatic cancer. Patients were given months more precious time with their loved ones.

“Crucially, these results suggest that daraxonrasib is able to keep the cancer under control for longer. There are now several KRAS inhibitor drugs in clinical trials around the world, which are showing promising results. We now need to ensure that these clinical trials are available in the UK, and that crucially these new treatment types are fast-tracked for approval – as recognised in the National Cancer Plan.

“Tragically, half of all people with pancreatic cancer die within just three months of their diagnosis. More time with those we love most is truly priceless. We must do everything possible to ensure the most promising new treatments are available here in the UK.”